Alnylam Pharma (ALNY) Misses Q1 EPS by 16c

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.21), $0.16 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.75 million.

At March 31, 2016, Alnylam had cash, cash equivalents and total marketable securities of $1.21 billion, as compared to $1.28 billion at December 31, 2015. In April 2016, the company entered into credit agreements described below with proceeds of $150.0 million of restricted marketable securities

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Bernstein SocGen Group Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
• Citi cuts Abercrombie rating after stock surge, lifts price target